Takahashi K, Takeuchi H, Fukai R, Nakamura H, Morihara K, Higashiyama Y, Takahashi T, Doi H, Tanaka F. Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment.
Front Immunol 2021;
12:625465. [PMID:
33659007 PMCID:
PMC7917254 DOI:
10.3389/fimmu.2021.625465]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2020] [Accepted: 01/27/2021] [Indexed: 11/13/2022] Open
Abstract
Here we report three cases of anti-myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD) mimicking multiple sclerosis in which seropositivity for anti-MOG antibodies occurred during disease-modifying drug dimethyl fumarate (DMF) treatment. These patients developed relapses with anti-MOG antibody seroconversion after switching from fingolimod or steroid pulse therapy to DMF, which was associated with peripheral lymphocyte recovery. MOGAD is considered a humoral immune disease, and DMF reportedly enhances Th2-skewed humoral immune activity. Therefore, we suggest that DMF, but not fingolimod, may exacerbate humoral immune imbalance and enhance autoantibody production, leading to aggravation of MOGAD.
Collapse